We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

105 hedge funds and large institutions have $1.02B invested in RAPT Therapeutics in 2025 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 36 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,387% more call options, than puts

Call options by funds: $22.1M | Put options by funds: $295K

513% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 8

300% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 9

139% more capital invested

Capital invested by funds: $428M → $1.02B (+$594M)

62% more funds holding

Funds holding: 65105 (+40)

9.04% more ownership

Funds ownership: 100.35%109.39% (+9%)

0% more funds holding in top 10

Funds holding in top 10: 99 (0)

Holders
105
Holders Change
+40
Holders Change %
+61.54%
% of All Funds
1.28%
Holding in Top 10
9
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
49
Increased
36
Reduced
9
Closed
8
Calls
$22.1M
Puts
$295K
Net Calls
+$21.8M
Net Calls Change
+$14.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$1.74M +$908K +29,228 +132%
BGM
52
Burkehill Global Management
New York
$1.69M +$1.55M +50,000 New
Connor, Clark & Lunn Investment Management (CC&L)
53
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.66M +$1.52M +49,021 New
Northern Trust
54
Northern Trust
Illinois
$1.37M +$729K +23,484 +138%
Rafferty Asset Management
55
Rafferty Asset Management
New York
$1.12M +$1.02M +32,984 New
Two Sigma Investments
56
Two Sigma Investments
New York
$1.05M -$115K -3,690 -11%
Point72 Asset Management
57
Point72 Asset Management
Connecticut
$853K +$398K +12,807 +103%
Squarepoint
58
Squarepoint
New York
$832K +$763K +24,572 New
GCP
59
GSA Capital Partners
United Kingdom
$777K +$385K +12,386 +117%
LCM
60
Landscape Capital Management
New Jersey
$774K +$710K +22,859 New
SPC
61
Sigma Planning Corp
Michigan
$644K +$590K +19,000 New
Man Group
62
Man Group
United Kingdom
$637K +$584K +18,802 New
Two Sigma Advisers
63
Two Sigma Advisers
New York
$625K +$573K +18,448 New
XT
64
XTX Topco
Cayman Islands
$616K +$565K +18,195 New
Acadian Asset Management
65
Acadian Asset Management
Massachusetts
$568K
BC
66
Birchview Capital
Vermont
$508K +$466K +15,000 New
BCM
67
Bridgeway Capital Management
Texas
$487K -$194K -6,250 -30%
EAM
68
Exome Asset Management
New York
$481K +$441K +14,194 New
HighTower Advisors
69
HighTower Advisors
Illinois
$424K -$3.11K -100 -0.8%
AIIC
70
AJU IB Investment Company
South Korea
$421K
PA
71
Profund Advisors
Maryland
$403K +$369K +11,892 New
OAC
72
OMERS Administration Corp
Ontario, Canada
$393K +$360K +11,600 New
YIH
73
Y-Intercept (HK)
Hong Kong
$381K +$349K +11,237 New
American Century Companies
74
American Century Companies
Missouri
$346K +$317K +10,218 New
Charles Schwab
75
Charles Schwab
California
$339K

RAPT Hedge Fund Activity: Q4 2025 in Review

105 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2025, worth a combined $1.02B — up 139% from $428M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new RAPT positions and 8 closed out — a net gain of 41 holders — while 36 added to existing stakes and 9 trimmed.

The largest buyer was FCPM III Services, adding an estimated $46.2M. The largest seller was Deep Track Capital, cutting an estimated $19.9M.

  • 105 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2025, up from 65 in Q3 2025.
  • Funds reported $1.02B of RAPT Therapeutics stock for Q4 2025, up 139% quarter-over-quarter.
  • 49 funds opened new RAPT Therapeutics positions in Q4 2025 and 8 closed out, a net change of +41 holders.
  • The largest RAPT Therapeutics buyer in Q4 2025 was FCPM III Services, an estimated $46.2M added.
  • The largest RAPT Therapeutics seller in Q4 2025 was Deep Track Capital, an estimated $19.9M sold.

Based on aggregated 13F filings for Q4 2025.